（文章来源：证券日报） 证券日报网讯 7月30日晚间，智飞生物发布公告称，公司及全资子公司——安徽智飞龙科马生物制药有 限公司、北京智飞绿竹生物制药有限公司于近日取得发明专利证书。 ...

每经AI快讯，智飞生物（SZ 300122，收盘价：24.69元）7月30日晚间发布公告称，重庆智飞生物制品 股份有限公司及全资子公司——安徽智飞龙科马生物制药有限公司、北京智飞绿竹生物制药有限公司于 近日取得中华人民共和国国家知识产权局颁发的发明专利证书。专利名称为"一种模板DNA分子及其在 制备mRNA和疫苗中的应用"。 2024年1至12月份，智飞生物的营业收入构成为：生物制品占比99.14%，其他业务占比0.86%。 截至发稿，智飞生物市值为591亿元。 每经头条（nbdtoutiao）——装个"AI脑"售价飙十倍！马斯克已下场，阿里、美团等大厂前高管正涌 入，这个万亿级赛道火了 （记者 曾健辉） ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-45 重庆智飞生物制品股份有限公司 | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | 一种模板 DNA 分 子及其在制备 | | | | 2022 年 07 月 | 2025 年 07 月 | 智飞生物 智飞绿竹 | | | ZL202210861511.7 | 第 8115265 号 | 发明专利 | | | | | mRNA 和疫苗中的 | | | | 20 日 | 29 日 | | | | | | | | | 智飞龙科马 | | 应用 | | | | | | | 上述发明专利是在公司自主研发的 mRNA 技术平台搭建过程中申请获得，未 来将在公司相关在研产品上应用。该专利证书的取得不会对公司近期生产经营产 生重大影响，但有利于进一步完善公司知识产权保护体系，充分发挥自主知识产 权优势，促进技术创新，提升公司的核心竞争力。 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 7 月 3 ...

Group 1 - As of July 29, the financing balance in the Shenzhen market reached 961.25 billion yuan, setting a new historical record, surpassing the previous high of 957.55 billion yuan on March 20 of this year [2] - Since June 23, the market has been on an upward trend, with the Shenzhen Composite Index surpassing 11,200 points [2] - The Shenzhen market has seen continuous net inflows of financing funds for six consecutive weeks, with a total net inflow amounting to 76.72 billion yuan, and weekly net inflows exceeding 10 billion yuan in the last four weeks [2] Group 2 - On July 29, five stocks in the Shenzhen market received net financing inflows exceeding 100 million yuan, including Xinyi Technology, CATL, Gree Electric Appliances, Zhifei Biological Products, and Guangli Microelectronics [2] - Xinyi Technology topped the list with a single-day net financing inflow of 1.14 billion yuan, marking a historical high for the stock [2] - As of July 29, the latest financing balance for Xinyi Technology was 7.78 billion yuan, reflecting a growth of 17.18% compared to the previous day [2]

Market Overview - The Shanghai Composite Index closed at 3609.71 points, above the annual line, with a change of 0.33% [1] - The total trading volume of A-shares reached 18293.09 billion yuan [1] Stocks Breaking Annual Line - A total of 26 A-shares have surpassed the annual line today, with notable stocks including Sinochem International, Dier Laser, and Blue Arrow Electronics, showing divergence rates of 8.45%, 4.04%, and 2.76% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Weimob Communication, Huaibei Mining, and Tongxiang Technology [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - Sinochem International: 10.10% increase, latest price 4.25 yuan, divergence rate 8.45% [1] - Dier Laser: 4.31% increase, latest price 60.98 yuan, divergence rate 4.04% [1] - Blue Arrow Electronics: 2.94% increase, latest price 21.68 yuan, divergence rate 2.76% [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Guangfeng Technology: 3.97% increase, latest price 15.72 yuan, divergence rate 2.62% [1] - Foster: 10.04% increase, latest price 14.69 yuan, divergence rate 2.44% [1] - I Love My Home: 2.56% increase, latest price 3.21 yuan, divergence rate 2.39% [1]

Market Overview - The Shanghai Composite Index rose by 0.33% on July 29, with 16 out of 28 sectors experiencing gains, led by the communication and steel industries, which increased by 3.29% and 2.59% respectively [1] - The pharmaceutical and biological industry ranked third in terms of daily gains, rising by 2.06% [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with the banking sector, saw declines of 1.36% and 1.19% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets reached 35.637 billion yuan, with only four sectors experiencing net inflows [1] - The pharmaceutical and biological sector led the net inflow with 2.996 billion yuan, followed by the steel sector with a net inflow of 419 million yuan [1] - The non-ferrous metals sector had the highest net outflow, totaling 4.434 billion yuan, followed by the machinery equipment sector with a net outflow of 3.792 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector saw a net inflow of 2.996 billion yuan, with 341 out of 474 stocks in the sector rising, including 11 stocks hitting the daily limit [2] - The top three stocks with the highest net inflow were: - Zhongsheng Pharmaceutical with a net inflow of 303 million yuan and a daily increase of 9.98% - Zhifei Biological with a net inflow of 256 million yuan and a daily increase of 6.50% - Jiuzhou Pharmaceutical with a net inflow of 250 million yuan and a daily increase of 10.01% [2] - Seven stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from: - Hengrui Medicine at 352 million yuan - Saili Medical at 187 million yuan - WuXi AppTec at 173 million yuan [2][4] Capital Inflow and Outflow Rankings - The top stocks by capital inflow in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: +9.98%, turnover rate 15.34%, inflow 302.59 million yuan - Zhifei Biological: +6.50%, turnover rate 9.19%, inflow 255.84 million yuan - Jiuzhou Pharmaceutical: +10.01%, turnover rate 12.54%, inflow 249.88 million yuan [2] - The top stocks by capital outflow included: - Hengrui Medicine: +2.84%, turnover rate 2.64%, outflow -352.45 million yuan - Saili Medical: -4.62%, turnover rate 28.21%, outflow -186.81 million yuan - WuXi AppTec: +7.72%, turnover rate 3.78%, outflow -173.05 million yuan [4]

减肥药概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002317 | 众生药 业 | 9.98 | 15.34 | 30259.16 | 13.39 | | 300122 | 智飞生 物 | 6.50 | 9.19 | 25584.13 | 8.11 | | 300765 | 新诺威 | 7.10 | 1.03 | 9329.48 | 13.00 | | 002294 | 信立泰 | 3.68 | 1.39 | 9194.53 | 11.73 | | 002038 | 双鹭药 业 | 7.09 | 9.67 | 7891.35 | 11.45 | | 002821 | 凯莱英 | 4.13 | 4.86 | 7719.47 | 4.12 | | 300199 | 翰宇药 业 | 4.97 | 21.02 | 7338.57 | 2.48 | | 000513 | 丽珠集 | 0.07 | 3.00 | ...

Group 1 - The recombinant protein concept sector rose by 2.90%, ranking second among concept sectors, with 41 stocks increasing in value [1][2] - Notable gainers in the sector included Ruizhi Pharmaceutical, which hit a 20% limit up, and other significant increases were seen in Sanyuan Gene (20.76%), Haite Biological (15.28%), and NuoSilande (11.14%) [1][2] - The sector experienced a net inflow of 1.22 billion yuan from main funds, with 33 stocks receiving net inflows, and six stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The leading stocks by net inflow included Zhifei Biological (net inflow of 256 million yuan), Ruizhi Pharmaceutical (235 million yuan), Chengdu XianDao (157 million yuan), and Shenzhou Cell (134 million yuan) [2][3] - The top three stocks by net inflow ratio were Shenzhou Cell (19.31%), Kaiyin Technology (16.57%), and Chengdu XianDao (16.19%) [3] - The overall market saw various concept sectors with mixed performances, with CRO concept leading at 4.00% increase, while sectors like pork and chicken saw declines of -1.35% and -1.12% respectively [2]

截至7月29日收盘，创新药概念上涨2.79%，位居概念板块涨幅第3，板块内，195股上涨，睿智医药20% 涨停，奥翔药业、亚太药业、九洲药业等涨停，三元基因、药石科技、南新制药等涨幅居前，分别上涨 20.76%、18.77%、17.01%。跌幅居前的有昂利康、*ST苏吴、多瑞医药等，分别下跌6.16%、5.04%、 4.66%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 837344 | 三元基因 | 34.84 | 20.76% | 14.39万 | | 4.83亿 | | 430047 | 诺思兰德 | 25.25 | 11.14% | 14.89万 | | 3.62亿 | | 301080 | 百普赛斯 | 56.66 | 8.07% | 5.96万 | | 3.28亿 | | 603590 | 康辰药业 | 60.15 | 7.93% | 14.36万 | | 8.41亿 | | 300122 | 智飞生物 | 25.06 | 6.50% | 129.92万 | | 31.54亿 | | 688136 | 科兴制药 | 50.47 | 6.41% | 11.16万 | | 5.51亿 | | 688293 | 奥浦迈 | 58.96 | 4.59% | 2.95万 | | 1.73亿 | | 300485 | 赛升药业 | 15.55 | 4.43% | 52.62万 | | 8.08亿 | ...